Ensysce Biosciences, Inc. (ENSC)
- Previous Close
0.5745 - Open
0.5900 - Bid 0.5671 x 100
- Ask 0.6178 x 100
- Day's Range
0.5501 - 0.6250 - 52 Week Range
0.5300 - 7.2000 - Volume
176,491 - Avg. Volume
554,766 - Market Cap (intraday)
4.431M - Beta (5Y Monthly) 0.76
- PE Ratio (TTM)
-- - EPS (TTM)
-4.6900 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
11.33
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.
www.ensysce.comRecent News: ENSC
Performance Overview: ENSC
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENSC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENSC
Valuation Measures
Market Cap
4.43M
Enterprise Value
4.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.68
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.41
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-155.91%
Return on Equity (ttm)
--
Revenue (ttm)
2.23M
Net Income Avi to Common (ttm)
-10.63M
Diluted EPS (ttm)
-4.6900
Balance Sheet and Cash Flow
Total Cash (mrq)
1.12M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-7.42M